Retatrutide 5mg

Retatrutide is an investigational triple receptor agonist currently under Phase 3 clinical evaluation, studied for its potential role in metabolic regulation and body composition research. Unlike earlier GLP-1 based compounds, Retatrutide simultaneously engages GLP-1, GIP, and glucagon receptor pathways — an architectural distinction that has positioned it as one of the most closely watched compounds in current metabolic science.

Read the Apex Research Series →

For research use only. Not for human consumption.

$50.00

Scroll to Top